Tumor lysis syndrome and metastatic melanoma.
Tumor lysis syndrome (TLS) is a potential emergent complication of oncologic treatment. TLS is commonly reported in hematological malignancies with rapid cell turnover rates, but is relatively rare in solid tumors. TLS is most frequently a result of cancer treatment in combination with a large tumor burden, but has occasionally been reported to occur spontaneously, especially in cases of advanced or metastatic disease. In this article, we describe the case of a patient with newly diagnosed metastatic melanoma that developed TLS two days after initiation of corticosteroids. In addition, we present a brief literature review of melanoma-associated TLS and review the etiology, diagnosis, and management of TLS.
Department of Medical Oncology, Saint Louis University School of Medicine, 1402 S. Grand Blvd, Saint Louis, MO, 63104, USA. meeks@slu.edu.
Marshall W
MW
Meeks
Department of Gastroenterology and Hepatology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
Muhammad B
MB
Hammami
Department of Pathology, Saint Louis University School of Medicine, Saint Louis, MO, USA.
Katherine J
KJ
Robbins
Department of Medical Oncology, Saint Louis University School of Medicine, 1402 S. Grand Blvd, Saint Louis, MO, 63104, USA.
Kevin L
KL
Cheng
Department of Medical Oncology, Saint Louis University School of Medicine, 1402 S. Grand Blvd, Saint Louis, MO, 63104, USA.
Jack M
JM
Lionberger
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000473:pathology
D000305:Adrenal Cortex Hormones
Corticosteroids; Melanoma; Oncologic emergency; Tumor lysis syndrome